SCHEMBL3284013

SCHEMBL3284013

O=C1Nc2ccccc2/C1=C\c1ccc2cccccc1-2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 5/20 1.00
RPS6KA3 P51812 3/20 0.64
ALK Q9UM73 3/20 0.64
NPC1 O15118 3/20 0.61
PLK4 O00444 2/20 0.61
PLK1 P53350 2/20 0.61
MAP3K7 O43318 1/20 0.61
TAB1 Q15750 1/20 0.61
RET P07949 4/20 0.56
NTRK1 P04629 3/20 0.56
PDGFRB P09619 3/20 0.56
KDR P35968 3/20 0.56
DAPK3 O43293 2/20 0.56
PRKD3 O94806 2/20 0.56
MAP4K4 O95819 2/20 0.56
LCK P06239 2/20 0.56
FYN P06241 2/20 0.56
CSF1R P07333 2/20 0.56
LTK P29376 2/20 0.56
MAPK8 P45983 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3284018 1.00 FLT3 (1.00) FLT3RPS6KA3ALKNPC1PLK4
SCHEMBL3285276 1.00 FLT3 (1.00) FLT3RPS6KA3ALKNPC1PLK4
SCHEMBL3290705 0.88 FLT3 (0.79) FLT3RPS6KA3ALKNPC1PLK4
SCHEMBL3283768 0.88 FLT3 (0.79) FLT3RPS6KA3ALKNPC1PLK4
SCHEMBL3283766 0.88 FLT3 (0.79) FLT3RPS6KA3ALKNPC1PLK4
SCHEMBL3284988 0.85 FLT3 (0.73) FLT3RPS6KA3ALKRETPDGFRB
SCHEMBL3285176 0.85 FLT3 (0.73) FLT3RPS6KA3ALKPDGFRBLRRK2
SCHEMBL13359321 0.85 FLT3 (0.73) FLT3RPS6KA3ALKNPC1PLK4
SCHEMBL3285170 0.85 FLT3 (0.73) FLT3RPS6KA3ALKNPC1PLK4
SCHEMBL3283704 0.85 FLT3 (0.73) FLT3RPS6KA3ALKNPC1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714146-B2 Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-05-11 US disclosed
US-7714146-B2 Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-05-11 US disclosed
US-7714146-B2 Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-05-11 US disclosed
US-20080125590-A1 Azulene compounds INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-05-29 US disclosed
US-20080125590-A1 Azulene compounds INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-05-29 US disclosed
US-20080125590-A1 Azulene compounds INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2008-05-29 US disclosed
EP-1918277-A2 Azulene compounds Industrial Technology Research Institute (TW) 2008-05-07 EP disclosed
EP-1918277-A2 Azulene compounds Industrial Technology Research Institute (TW) 2008-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125590-A1 Azulene compounds AZI2, PRMT5, BRCA1 FLT3 796/4885RPS6KA3 654/4885ALK 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.